What is Igenica?
Igenica operates at the intersection of cutting-edge biotechnology and strategic healthcare innovation. The company is recognized for its commitment to advancing rigorous scientific platforms, positioning itself as a key player in the development of novel therapies. By leveraging a robust digital presence and a focus on original research, Igenica has established a reputation for excellence, attracting significant interest from investors who specialize in the complex, high-stakes environment of modern medicine and biotech commercialization.
How much funding has Igenica raised?
Igenica has raised a total of $37.9M across 6 funding rounds:
Series A
$6.2M
Series B
$16.1M
Series C
$7M
Multiple Rounds
$8.5M
Series A (2009): $6.2M with participation from The Column Group, OrbiMed Advisors, LLC, and 5AM Venture Management, LLC
Series B (2010): $16.1M led by OrbiMed Advisors, LLC, 5AM Venture Management, LLC, and Third Rock Ventures
Series C (2014): $7M supported by 5AM Ventures, OrbiMed, The Column Group, and Third Rock Ventures
Private Equity (2015): $5.1M featuring The Column Group, Third Rock Ventures, LLC, OrbiMed Advisors, LLC, and 5AM Venture Management, LLC
Private Equity (2015): $1.2M backed by OrbiMed Advisors, LLC, 5AM Venture Management, LLC, The Column Group, and Third Rock Ventures
Private Equity (2015): $2.3M, investors not publicly disclosed
Key Investors in Igenica
OrbiMed Advisors, LLC
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
5AM Venture Management, LLC
A life science-focused venture capital firm that partners with founders to fund rigorous science and bring new therapies to patients.
Third Rock Ventures, LLC
A healthcare venture firm dedicated to discovering and building companies that address disruptive areas of science and medicine.
What's next for Igenica?
With the infusion of $2.3M, Igenica is well-positioned to accelerate its pipeline development and expand its market footprint. The company's strategic roadmap likely involves scaling its core technology platforms and deepening its collaborative efforts with existing institutional partners. As it moves into its next phase of growth, Igenica will focus on translating its scientific breakthroughs into tangible clinical outcomes, further enhancing its value proposition for stakeholders and patients alike in the evolving healthcare ecosystem.
See full Igenica company page
